Literature DB >> 16023599

Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.

Clodagh C O'Shea1, Conrado Soria, Bridget Bagus, Frank McCormick.   

Abstract

ONYX-015 is an E1B-55K-deleted adenovirus that has promising clinical activity as a cancer therapy. However, many tumor cells fail to support ONYX-015 oncolytic replication. E1B-55K functions include p53 degradation, RNA export, and host protein shutoff. Here, we show that resistant tumor cell lines fail to provide the RNA export functions of E1B-55K necessary for ONYX-015 replication; viral 100K mRNA export is necessary for host protein shutoff. However, heat shock rescues late viral RNA export and renders refractory tumor cells permissive to ONYX-015. These data indicate that heat shock and late adenoviral RNAs may converge upon a common mechanism for their export. Moreover, these data suggest that the concomitant induction of a heat shock response could significantly improve ONYX-015 cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023599     DOI: 10.1016/j.ccr.2005.06.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  42 in total

1.  Adenovirus ubiquitin-protein ligase stimulates viral late mRNA nuclear export.

Authors:  Jennifer L Woo; Arnold J Berk
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

2.  E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.

Authors:  S C Cheong; Y Wang; J-H Meng; R Hill; K Sweeney; D Kirn; N R Lemoine; G Halldén
Journal:  Cancer Gene Ther       Date:  2007-11-23       Impact factor: 5.987

Review 3.  Viruses as anticancer drugs.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

Review 4.  Virotherapy: cancer gene therapy at last?

Authors:  Alan E Bilsland; Pavlina Spiliopoulou; T R Jeffry Evans
Journal:  F1000Res       Date:  2016-08-30

Review 5.  Oncolytic virotherapy for pancreatic cancer.

Authors:  Sonia Wennier; Shoudong Li; Grant McFadden
Journal:  Expert Rev Mol Med       Date:  2011-05-18       Impact factor: 5.600

6.  Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma.

Authors:  Chun-Yu Qian; Kai-Li Wang; Fan-Fu Fang; Wei Gu; Feng Huang; Fu-Zhe Wang; Bai Li; Li-Na Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  HSF1 overexpression enhances oncolytic effect of replicative adenovirus.

Authors:  Cheng Wang; Zhehao Dai; Rong Fan; Youwen Deng; Guohua Lv; Guangxiu Lu
Journal:  J Transl Med       Date:  2010-05-06       Impact factor: 5.531

8.  Adenovirus E4-ORF3 Targets PIAS3 and Together with E1B-55K Remodels SUMO Interactions in the Nucleus and at Virus Genome Replication Domains.

Authors:  Jennifer M Higginbotham; Clodagh C O'Shea
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

9.  p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication.

Authors:  Engin Gürlevik; Norman Woller; Peter Schache; Nisar P Malek; Thomas C Wirth; Lars Zender; Michael P Manns; Stefan Kubicka; Florian Kühnel
Journal:  Nucleic Acids Res       Date:  2009-05-14       Impact factor: 16.971

10.  Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.

Authors:  Guangyu Ma; Hideaki Shimada; Kenzo Hiroshima; Yuji Tada; Nobuo Suzuki; Masatoshi Tagawa
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.